Publications

• 
  
• Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9
  Sagrieya, H., Berube, C., Wen, A., Ramakrishnan, R., Mir, A., Hamilton, A., & Altman, R. B. (2010). Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. PHARMACOGENETICS AND GENOMICS, 20(7), 407–13.
• Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience
  Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., Majeti, R., … Medeiros, B. C. (2010). Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. AMERICAN JOURNAL OF HEMATOLOGY, 85(11), 877–881.
• Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer Lee, R., Wen, A., & Berube, C. (2011). Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 68(9), 814–817.
  
• 
  
• 
  
• Accessory splenules in autoimmune hemolytic anemia. Logan, A., Berube, C., & Gotlib, J. (2013). Accessory splenules in autoimmune hemolytic anemia. American Journal of Hematology, 88(2), 156-?
  
• 
  
• 
  
• Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. Liedtke, M., Dunn, T., Dinner, S., Coutré, S. E., Berube, C., Gotlib, J., … Medeiros, B. (2014). Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. Leukemia Research, 38(12), 1441–1445.
  
• Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. Narayan, R., Garcia, J. S., Percival, M.-E. M., Berube, C., Coutre, S., Gotlib, J., … Medeiros, B. C. (2016). Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. Leukemia & Lymphoma, 57(3), 609–615.
  
• Eculizumab Induces Sustained Remission in a Patient With Refractory Primary Catastrophic Antiphospholipid Syndrome Zikos, T. A., Sokolove, J., Ahuja, N., & Berube, C. (2015). Eculizumab Induces Sustained Remission in a Patient With Refractory Primary Catastrophic Antiphospholipid Syndrome. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 21(6), 311–313.
  
• A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. Dunn, T. J., Dinner, S., Price, E., Coutré, S. E., Gotlib, J., Hao, Y., … Liedtke, M. (2016). A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. British Journal of Haematology, 173(2), 253–59.
  
• 
  
• Magnitude of Potentially Inappropriate Thrombophilia Testing in the Inpatient Hospital Setting. Mou, E., Kwang, H., Hom, J., Shieh, L., Kumar, A., Richman, I., & Berube, C. (2017). Magnitude of Potentially Inappropriate Thrombophilia Testing in the Inpatient Hospital Setting. Journal of Hospital Medicine, 12(9), 735–38.
  
• Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. DeAngelo, D. J., George, T. I., Linder, A., Langford, C., Perkins, C., Ma, J., … Gotlib, J. (2017). Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia.
  
• 
  
•